These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 14682278)

  • 1. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Didanosine intensification in NRTI-experienced patients.
    Currier J
    AIDS Clin Care; 2003 Nov; 15(11):96. PubMed ID: 14682278
    [No Abstract]   [Full Text] [Related]  

  • 2. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abacavir as initial therapy and as a once-daily drug.
    Sax PE
    AIDS Clin Care; 2003 Nov; 15(11):93-4. PubMed ID: 14682271
    [No Abstract]   [Full Text] [Related]  

  • 3. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Prognosis after triple-class failure.
    Currier J
    AIDS Clin Care; 2003 Nov; 15(11):95. PubMed ID: 14682274
    [No Abstract]   [Full Text] [Related]  

  • 4. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
    [No Abstract]   [Full Text] [Related]  

  • 5. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). New NNRTI resistance mutations.
    Sax PE
    AIDS Clin Care; 2003 Nov; 15(11):96. PubMed ID: 14682277
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea in HIV therapy.
    HIV Hotline; 1998 Mar; 8(1):5-7. PubMed ID: 11365359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Single agent therapy for HIV infection?
    Currier J
    AIDS Clin Care; 2003 Nov; 15(11):96. PubMed ID: 14682276
    [No Abstract]   [Full Text] [Related]  

  • 9. Meeting notes from ICAAC. NRTI-only regimens: making a comeback?
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):8-9. PubMed ID: 15717378
    [No Abstract]   [Full Text] [Related]  

  • 10. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). New CCR5 antagonist shows antiretroviral effect.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):94-5. PubMed ID: 14682273
    [No Abstract]   [Full Text] [Related]  

  • 11. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T-1249 for T-20 salvage.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):95-6. PubMed ID: 14682275
    [No Abstract]   [Full Text] [Related]  

  • 12. Combining d4T/ddI looks promising.
    Posit Aware; 1996; 7(1):7. PubMed ID: 11363129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
    [No Abstract]   [Full Text] [Related]  

  • 14. French investigators warn of LPV/TDF/ddI interaction.
    Carter M
    IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
    Negredo E; Garrabou G; Puig J; Lòpez S; Morén C; Bellido R; Ayen R; Cardellach F; Miró O; Clotet B
    Antivir Ther; 2008; 13(2):231-40. PubMed ID: 18505174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients.
    Dragovic G; Jevtovic D
    Biomed Pharmacother; 2012 Jun; 66(4):308-11. PubMed ID: 22658063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selected highlights from ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy).
    TreatmentUpdate; 2002 Jan; 14(1):5-10. PubMed ID: 12141238
    [No Abstract]   [Full Text] [Related]  

  • 19. Review of viral load and combination therapy data from 35th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
    Bray JM
    STEP Perspect; 1995; 7(3):10-1. PubMed ID: 11362980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
    Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
    Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.